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Abstract
Background: To analyze the clinical presentation and complications of varicella zoster virus (VZV) infection in children
with rheumatic diseases treated with immunosuppressive medication such as biological disease-modifying antirheumatic
drugs (bDMARDs) and/or conventional disease-modifying antirheumatic drugs (cDMARDs), and to analyze the therapeutic
approach to VZV infections with respect to the concomitant immunosuppressive treatment.
Methods: Retrospective multicenter study using the Swiss Pediatric Rheumatology registry. Children with rheumatic
diseases followed in a Swiss center for pediatric rheumatology and treated with cDMARD and/or bDMARD with a clinical
diagnosis of varicella or herpes zoster between January 2004 and December 2013 were included.
Results: Twenty-two patients were identified, of whom 20 were treated for juvenile idiopathic arthritis, 1 for a
polyglandular autoimmune syndrome type III, and 1 for uveitis. Of these 22 patients, 16 had varicella and 6 had
herpes zoster. Median age at VZV disease was 7.6 years (range 2 to 17 years), with 6.3 years (range 2 to 17 years)
for those with varicella and 11.6 years (range 5 to 16 years) for those with herpes zoster. The median interval
between start of immunosuppression and VZV disease was 14.1 months (range 1 to 63 months). Two patients
had received varicella vaccine (1 dose each) prior to start of immunosuppression. Concomitant
immunosuppressive therapy was methotrexate (MTX) monotherapy (n = 9) or bDMARD monotherapy (n = 2), or a
combination of bDMARD with prednisone, MTX or Leflunomide (n = 11). Four patients experienced VZV related
complications: cellulitis in 1 patient treated with MTX, and cellulitis, sepsis and cerebellitis in 3 patients treated
with biological agents and MTX combination therapy. Six children were admitted to hospital (range of duration:
4 to 9 days) and 12 were treated with valaciclovir or aciclovir.
Conclusion: The clinical course of varicella and herpes zoster in children under immunosuppression is variable,
with 4 (18 %) of 22 children showing a complicated course. Thorough assessment of VZV disease and vaccination
history and correct VZV vaccination according to national guidelines at diagnosis of a rheumatic autoimmune
disease is essential to minimize VZV complications during a later immunosuppressive treatment.
Keywords: Varicella zoster virus, Pediatric, Rheumatic autoimmune disease, Immunosuppression
* Correspondence: andreas.woerner@ukbb.ch
7Pediatric Rheumatology, University of Basel Children’s Hospital, Spitalstrasse
33, CH – 4031 Basel, Switzerland
Full list of author information is available at the end of the article
© 2016 Leuvenink et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Leuvenink et al. Pediatric Rheumatology  (2016) 14:34 
DOI 10.1186/s12969-016-0095-3
Background
In the absence of a universal childhood immunization
program for varicella zoster virus (VZV), VZV infection is
widely spread in the Swiss pediatric population. By the age
of 14 years, 95 % of children are seropositive for VZV [1].
The clinical features of VZV infection are determined by
primary infection leading to varicella (chickenpox) and en-
dogenous reactivation leading to herpes zoster (shingles).
The most frequent complications of varicella are second-
ary infections, notably cellulitis, abscesses, pneumonia,
sepsis and fasciitis, mainly caused by Staphylococcus aur-
eus or group A β-hemolytic streptococci. Complications
of the central nervous system may present as cerebellar
ataxia, meningoencephalitis or cerebral vasculitis [2].
Children diagnosed with a rheumatic autoimmune dis-
ease (e.g., juvenile idiopathic arthritis) are frequently
treated with immunosuppressants to reduce disease activ-
ity. Immunosuppressive medication includes conventional
disease-modifying anti-rheumatic drugs (cDMARDs),
such as methotrexate or leflunomide, and a growing
number of biological disease-modifying anti-rheumatic
drugs (bDMARDs), such as inhibitors of tumor necro-
sis factor-alpha (e.g., etanercept, adalimumab, inflixi-
mab), T-cell co-stimulation (abatacept), interleukin-1
(anakinra, canakinumab), interleukin-6 (tocilizumab) or
inductors of B-cell depletion (rituximab). Each of these
drugs are known to increase susceptibility to infectious
diseases and complications thereof [3].
The aim of this retrospective study was to assess the
clinical characteristics of VZV disease in children with
rheumatic diseases under immunosuppression. A second
aim was to assess the therapeutic approach to VZV dis-
ease under immunosuppression.
Methods
Study design
This was a retrospective multicenter study based on the
Swiss Pediatric Rheumatology Register. The Swiss Pediatric
Rheumatology Register was established in 2004, including
all patients seen in the 8 centers for pediatric rheuma-
tology in Switzerland (Aarau, Basel, Bern, Chur, Lausanne,
Lucerne, St. Gallen and Zurich). Available data from the
register were date of birth, sex, age at diagnosis, diagnosis
and disease details. All centers but one agreed to partici-
pate in this study. Detailed information addressing differ-
ent clinical and therapeutic parameters of VZV disease
were obtained by a specific questionnaire (available from
the authors by request).
Patients
Patients who developed varicella or herpes zoster during
the study period (January 2004 to December 2013) while
being treated with conventional and/or biological DMARDs
in one of the participating Swiss centers for pediatric
rheumatology were included for analysis.
Data collection
The seven participating centers received a standardized
questionnaire and were asked to identify patients who
fulfilled the inclusion criteria. The collected detailed data
were returned to the investigators in Basel (RL, UH,
AW). Besides inclusion of the basic characteristics from
the register, the questionnaire included the following
variables: age at occurrence of VZV disease, VZV vaccin-
ation status, previous varicella or herpes zoster, medica-
tion at onset of VZV disease, rash (varicella: atypical, i.e.,
<100 vesicles or typical, i.e., ≥100 vesicles; herpes zoster:
segment), complications, hospitalization, treatment. Fur-
thermore it included impact on immunosuppressive medi-
cation and possible changes in rheumatic disease activity
as assessed by the treating physician six months after the
occurrence of VZV manifestation.
Data analysis
Data from the questionnaire was entered into a database
(Microsoft Office Excel, Microsoft, USA). Descriptive
analysis was performed with SPSS, IBM, USA.
Ethics
The Swiss Pediatric Rheumatology Register received eth-
ical approval by the University of Lausanne (No. 101/02).
Results
On 31st December 2013, 2452 patients with rheumatic
diseases were included in the registry.
Of these, twenty-two patients fulfilled the inclusion cri-
teria, with 16 patients presenting with varicella and 6 pa-
tients with herpes zoster. The median age of the patients
was 7.6 years (range 2 – 17 years). Sixteen were female.
Two patients had been vaccinated (1 dose) against
VZV. A serology proving seroprotection against VZV
after vaccination had not been performed. Twenty pa-
tients had a diagnosis of juvenile idiopathic arthritis;
one patient was diagnosed with polyglandular auto-
immune syndrome type III and one patient with anter-
ior uveitis. Immunosuppressive therapy at the onset of
VZV manifestation was methotrexate (MTX) mono-
therapy (n = 9) or bDMARD monotherapy (etanercept,
n = 2), or a combination of bDMARD with prednisone,
MTX or Leflunomide (n = 11).
Patients with varicella
Baseline characteristics for patients are shown Table 1. Of
the 16 patients with varicella, 11 were female and the me-
dian age of the patients was 6.3 years (range 2.5 – 17.4).
Nine of 16 varicella manifestations in total occurred
within the first 12 months after the introduction of
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immunosuppressive therapy (median 10.5 months, range
1.1 – 30.3 months). Four of 16 varicella manifestations oc-
curred with a mild presentation (less than 100 vesicles)
while the other 12 cases showed a typical manifestation
(more than 100 vesicles). Two patients had previously re-
ceived a single-dose of varicella vaccine. Both showed a
non-complicated clinical course, but yet one of them re-
ceived intravenous aciclovir for 7 days to treat the infection.
Complications of VZV manifestation emerged in 4 of
16 varicella patients. The complications included cellu-
litis in three patients (one additionally presented with a
septic condition) and cerebellitis in one patient. Five of
16 patients were admitted to hospital for a median of
6 days (range 4 –9 days) (Table 1). Ten patients, includ-
ing the 4 with complications, had been treated with anti-
viral medication: 9 patients had received aciclovir, one
patient valaciclovir. Median duration of treatment was
7 days (range 5 to 8 days).
Patients with herpes zoster
Six patients developed herpes zoster while under im-
munosuppression for underlying rheumatic disease; their
median age was 11.6 years (range 5.9 – 16.5). Median
time to event was 8.4 months (range 4.1 – 63 months).
Four of the six cases with herpes zoster occurred within
the first 12 months of the onset of the immunosuppres-
sive therapy.
No complications were observed in the six patients
with herpes zoster; one patient was admitted to hospital
(Table 1). Two patients had been treated with antiviral
medication (aciclovir and valaciclovir, one each). In pa-
tients 21 and 22, the dermatomes were reported, with
the former suffering from herpes zoster in the lumbar
dermatome L1 on the left hand side and the latter being
affected in the dermatome of the first branch of the tri-
geminal nerve.
Impact on immunosuppressive treatment and change in
activity of baseline disease
Immunosuppressive treatment was continued in 11 of 21
patients (unknown in one case). In patients with MTX
monotherapy (n = 9), immunosuppressive treatment was
interrupted in only 2 patients. If two immunosuppressive
medications were used, immunosuppressive medication
was interrupted in 7 of 11 patients. Two patients contin-
ued their baseline medication despite occurrence of com-
plications (1 cellulitis, 1 cerebellitis). After interruption,
the immunosuppressive therapy was restarted within one
(n = 5), two (n = 4) or three weeks (n = 1) after VZV mani-
festation. Retrospective assessment of overall disease
activity by the treating physician (expert opinion) six
months after VZV manifestation was reported to be un-
changed in 15 patients, less active in three patients, more
active in three patients and unknown in one patient.
Discussion
The aim of our study was to assess the presentation and
complications of VZV manifestation in children with
rheumatic autoimmune diseases under immunosuppres-
sion. The clinical course of varicella and herpes zoster and
their potential complications is well known, but solid in-
formation about the clinical presentation and the efficacy
of treatment in these patients is scarce. Switzerland is a
country with a high incidence of varicella, because vari-
cella vaccination is only recommended for the 11 to
39 years old healthy population with a negative varicella
history or negative VZV-specific IgG antibodies [4]. There-
fore, most of the children experience varicella with a peak
of VZV seroconversion at 3 to 8 years [2, 5]. The majority
of patients with pediatric rheumatic diseases, especially
JIA, is also diagnosed within the same age range. As iatro-
genic immunosuppression and immune dysfunction are
risk factors for complications during VZV infection, the
current Swiss Federal Office of Public Health vaccination
plan recommends varicella vaccination for patients with
autoimmune diseases without immunosuppressive treat-
ment. However, these recommendations frequently inter-
fere with an urgent need to start immunosuppressive
medication, often leading to a postponement of vaccin-
ation and thereby increasing the risk for varicella.
Occurrence of varicella under iatrogenic immunosup-
pression in children with juvenile idiopathic arthritis has
been reported in several studies addressing the safety of
bDMARDs [3]. However, detailed published data ad-
dressing the outcome of such cases are scarce. Wieger-
ing et al. reported two immunocompromised patients
with JIA that showed varicella without complications
under aciclovir treatment [6]. In a study addressing the
safety of etanercept in 25 children with JIA under four
years of age, two patients developed varicella, of whom
one was complicated by necrotizing fasciitis [7]. In our
study, the clinical presentation of varicella was typical or
mild in most of the patients. However, four of the 16 pa-
tients with varicella developed complications which oc-
curred under both single-drug and combination therapy.
Cellulitis was the most frequent complication, as it is the
case in the healthy population [1, 8, 9]. Systemic complica-
tions presenting as sepsis were observed in one patient,
which is a rare complication of varicella in immunocom-
petent patients [10, 11]. Due to the retrospective nature of
this study, a calculation of the complication rate was not
possible. However, it may exceed the reported rate of se-
vere complications of about 1/100′000 from population
based European studies [12].
Interestingly, two patients with varicella had previously
received a first dose of varicella vaccine two and four
weeks before the introduction of methotrexate, respect-
ively, and one patient 8 years of age had a history of pre-
vious varicella at 6 months of age. In large studies, a
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single dose of varicella vaccine regimen has been shown
to be only 80 to 85 % effective in preventing varicella
[13, 14], therefore, a two-dose schedule has been imple-
mented in most of the countries, including Switzerland.
Cell-mediated immunity plays a crucial role in control-
ling varicella disease and in inducing protection [15, 16],
and the immunosuppressive treatment possibly influ-
enced VZV immunity in these two patients [17].
Concerning antiviral treatment, only 12 of the 22
patients had been treated with aciclovir or valaciclovir.
The absence of antiviral treatment in the remaining 10
patients did not result in any complication.
We were surprised that none of the 22 patients had
been treated with anti-VZV immunoglobulins. Two
possible explanations may contribute to this finding:
First, awareness of this therapeutic approach was poten-
tially not yet sufficiently established in the early study
period [18, 19]. Second, the time window for a post-
exposure treatment (usually within 96 h) might have
been missed in some of these patients.
Herpes zoster in healthy children is rare. Recently,
Weinmann et al. [20] estimated an incidence of HZ of
230 per 100′000 patient-years in a healthy population.
In non-VZV vaccinated children with JIA exposed to
Table 1 Baseline characteristics, VZV disease characteristics and impact on immunosuppressive treatment
Baseline characteristics VZV disease characteristics Impact on
immunosuppressive
treatment
Case Sex/Age
(years)
Diagnosis Medication at
onset of VZV
VZV
vaccine
doses
Time to
event
(months)
Date of
onset
Rash Complications Hosp. Treatment Dur. Management of
immunosuppression
Varicella
1 F/4.8 JIA MTX 0 15.1 05/2004 typical cellulitis 6d ACV i.v. + AB 7d unknown
2 F/6.3 JIA MTX 0 14.9 06/2005 typical none no no - continued
3 F/6.3 JIA MTX 0 14.2 01/2006 typical none no no - continued
4 F/3.0 JIA MTX 0 6.2 01/2007 typical none no no - continued
5 F/6.1 JIA MTX + INF 0 17.6 02/2008 typical cellulitis,
sepsis
9d ACV i.v. + AB 7d interrupted
6 F/3.7 JIA ETA 0 4.2 02/2009 typical none no ACV i.v. n.a. interrupted
7 F/3.4 JIA MTX + ETA 0 8.6 04/2009 typical none no no - interrupted
8 F/2.5 JIA ETA 0 4.4 03/2010 typical cellulitis no ACV p.o. + AB 7d continued
9 F/17.4 JIA MTX 1 29.9 10/2010 typical none no no - continued
10 M/8.9 JIA MTX + ADA 0 21.7 02/2011 typical cerebellitis 5d ACV i.v. 7d continued
11 M/8.8 JIA MTX + INF 0a 5.7 04/2011 atypical none no no - continued
12 F/7.2 JIA MTX 0 3 02/2012 typical none 5d ACV i.v. 5d interrupted
13 F/6.2 JIA MTX + TCZ 0 1.1 03/2012 atypical none no ACV p.o. 8d interrupted
14 M/4.0 JIA MTX 0 12.4 04/2012 atypical none no VCV p.o. 7d interrupted
15 M/4.1 JIA TCZ + Pred. 0 3.2 06/2012 typical none 6d ACV i.v. 6d interrupted
16 M/7.5 JIA MTX + INF 1 30.3 04/2013 atypical none no ACV i.v. + p.o. 7d interrupted
Herpes zoster
17 F/6.4 JIA MTX 0 5.5 04/2004 n.a. none no no - continued
18 F/14.7 JIA MTX + ADA 0 10.9 10/2004 n.a. none no no - continued
19 F/5.9 JIA MTX 0 4.1 01/2005 n.a. none no no - continued
20 M/13.6 PAS III RTX + Pred. 0 6 12/2008 n.a. none no no - continued
21 F/9.5 JIA LEF + INF 0 27.6 07/2011 Lumbar 1,
left
none no VCV p.o. n.a. interrupted
22 F/16.5 Ant. Uv. MTX + INF 0 63 11/2013 Trigeminal
ophthalmic
nerve, left
none 4d ACV iv. + p.o.b 7d interrupted
ahad a history of varicella at the age of 6 months. Hosp hospitalization, Dur duration, MTX methotrexate, ETA etanercept, INF infliximab, ADA adalimumab,
TCZ tocilizumab, Pred prednisone, VCV valaciclovir, ACV aciclovir, AB antibiotics; balso received local aciclovir. LEF leflunomide, RTX rituximab, JIA juvenile
idiopathic arthritis, Ant. uv anterior uveitis, PAS polyglandular autoimmune syndrome, n/a not available
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biologics, a German register-based study reporting on 17
herpes zoster events calculated an incidence of 3.1/1000
patient years (95 % CI, 1.9–4.9) [21]. Two of the patients
with a known outcome experienced complications (inter-
costal neuralgia and recurrent herpes zoster). The largest
study reporting on JIA patients and herpes zoster has been
published by Beukelman et al. [22]. Using US Medicaid
administrative claims data on 8500 JIA patients with
360000 children diagnosed with attention deficit hyper-
activity disorder used as comparator group, this study
found an incidence rate of 225 per 100′000 person years
and an incidence risk ratio of 2.1 (95 % CI, 1.4–3.0).
Beukelman et al. did not observe a significant association
between the occurrence of herpes zoster and the use of a
specific immunosuppressive medication.
Our study reported HZ in six children without further
complications. Of note, four presented early within less
than 12 months after onset of the immunosuppressive
therapy. This observation underscores that iatrogenic
immunosuppression may favor reactivation of latent
Herpesviridae diseases [23].
Data on hospitalization for varicella in childhood,
including Switzerland, report rates of 9–10/1000
patients [24]. In our study, 27 % of the patients were
admitted to hospital, either for a VZV-associated compli-
cation or an intravenous antiviral treatment. Thus, the
hospitalization rate of immunosuppressed patients is
influenced by the decision of an intravenous antiviral
treatment and could be, as in this study, remarkably
higher than in the general population.
Half of the pediatric rheumatologists did continue im-
munosuppressive medication during VZV manifestation.
Most of the specialists continued methotrexate treatment,
as this medication has a long half-life. Combination ther-
apy was associated with a higher interruption of therapy;
two thirds of the patients paused the immunosuppressive
medication during VZV manifestation. The heterogeneous
therapeutic approach probably reflects the absence of
established guidelines in this clinical situation.
Our study has several limitations. First, even though col-
lected from a register, our data are of retrospective nature,
and not all data were available concerning the management
of VZV manifestations. Second, the retrospective setting
implies a risk of underreporting, and a calculation of VZV
manifestation incidence und complication rates was not
possible from the existing data. Third, assessment of overall
disease activity of the underlying autoimmune disease sub-
sequent to VZV disease was not possible to be based on
validated disease activity scores. Thus, potential changes in
disease activity represent only an expert opinion, reflecting
the clinical follow up of an individual patient. Fourth, our
study was too small to allow recommendations for VZV
treatment and handling of immunosuppressive medication
during VZV infection in immunosuppressed patients with
rheumatic autoimmune diseases. This should be assessed in
larger studies in the future.
Conclusion
In conclusion, this study shows that the clinical presen-
tation of VZV disease in children with rheumatic auto-
immune diseases under immunosuppression may be
altered in respect to complication rate and hospitalization
rate. To prevent the occurrence of varicella or herpes zos-
ter, thorough assessment of VZV infection or vaccination
prior to immunosuppression and correct and timely VZV
vaccination according to national guidelines is essen-
tial to minimise VZV complications in this vulnerable
population.
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